228 related articles for article (PubMed ID: 16750913)
1. Antisense molecules for targeted cancer therapy.
Wacheck V; Zangemeister-Wittke U
Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential.
Olie RA; Zangemeister-Wittke U
Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155
[TBL] [Abstract][Full Text] [Related]
4. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotide therapy in urology.
Kausch I; Böhle A
J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
[TBL] [Abstract][Full Text] [Related]
6. Antisense therapy for cancer.
Gleave ME; Monia BP
Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 family members as molecular targets in cancer therapy.
Marzo I; Naval J
Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
[TBL] [Abstract][Full Text] [Related]
8. Antisense strategy in hematological malignancies.
Warzocha K
Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
10. [Antisense oligonucleotides: a new therapeutic approach].
Guinot P; Temsamani J
Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
[TBL] [Abstract][Full Text] [Related]
11. A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy.
Tidd DM
Anticancer Res; 1990; 10(5A):1169-82. PubMed ID: 2241097
[TBL] [Abstract][Full Text] [Related]
12. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
13. Making sense of antisense.
Vidal L; Blagden S; Attard G; de Bono J
Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method.
Yildiz D; Oztas H; Hilal Ates B
Med Hypotheses; 2005; 64(2):328-32. PubMed ID: 15607566
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy developments for pancreatic cancer.
Bhattacharyya M; Lemoine NR
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):285-98. PubMed ID: 16549328
[TBL] [Abstract][Full Text] [Related]
16. [Prospects for antisense therapy].
Maekawa T
Rinsho Ketsueki; 1995 May; 36(5):410-8. PubMed ID: 7783344
[TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
18. RNA molecules as anti-cancer agents.
Friedrich I; Shir A; Klein S; Levitzki A
Semin Cancer Biol; 2004 Aug; 14(4):223-30. PubMed ID: 15219615
[TBL] [Abstract][Full Text] [Related]
19. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
Sommer W; Heilig M
Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Bcl-2 family in cancer therapy.
Papadopoulos K
Semin Oncol; 2006 Aug; 33(4):449-56. PubMed ID: 16890799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
